Category Archives: News and Events

BriaCell Therapeutics Announces Closing of Offering

PHILADELPHIA & VANCOUVER, British Columbia, June 02, 2026 (GLOBE NEWSWIRE) — BriaCell Therapeutics Corp. (Nasdaq: ...

BriaCell Presents Positive Clinical Data at ASCO 2026

Final Bria-IMT™ Phase 2 data show 55% >1 year and 27% >2-year survival in heavily ...

BriaCell Therapeutics Announces Pricing of Offering

PHILADELPHIA and VANCOUVER, British Columbia, May 31, 2026 (GLOBE NEWSWIRE) — BriaCell Therapeutics Corp. (Nasdaq: ...

BriaCell Receives Positive Recommendation from Data Safety Monitoring Board (DSMB) for Phase 3 Study in Metastatic Breast Cancer

Independent DSMB has identified no safety concerns, to date, and recommends continuation of BriaCell’s pivotal ...

BriaCell Presentations Highlight Positive Clinical Data for Bria-IMT(TM) at ASCO 2026

Final Phase 2 Bria-IMT median overall survival (OS) is 16.6 months (with Phase 3 formulation) ...

BriaCell Expands Pipeline to Include an Ovarian Cancer Immunotherapy Candidate, Bria-OVA+(TM)

BriaCell expands push in women’s health, building on Phase 2 success in advanced metastatic breast ...

BriaCell Completes Manufacturing of Clinical Supplies of Bria-PROS+(TM) for Prostate Cancer

Bria-PROS+ is BriaCell’s next generation personalized off-the-shelf immunotherapy for prostate cancer Immune stimulating components of ...

BriaCell Adds Penn Medicine’s Abramson Cancer Center as Clinical Site in Pivotal Phase 3 Breast Cancer Study

Other recently activated sites include Indiana University Melvin and Bren Simon Comprehensive Cancer Center, University ...

BriaCell Phase 3 Bria-IMT(TM) Study Enrollment Surpasses 230 Patients

Over 315 patients screened and over 230 patients enrolled in BriaCell’s pivotal Phase 3 Bria-ABC ...

BriaCell Adds NYU Langone Health’s Perlmutter Cancer Center as Clinical Site in Pivotal Phase 3 Breast Cancer Study

PHILADELPHIA and VANCOUVER, British Columbia, May 07, 2026 (GLOBE NEWSWIRE) — BriaCell Therapeutics Corp. (Nasdaq: ...